(Q38083489)

English

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

scientific article published on 21 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

21 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Genetics in Medicine

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

517-527

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Targeting the epidermal growth factor receptor in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Spotlight on panitumumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Panitumumab: a review of its use in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

KRAS and BRAF: drug targets and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation.

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

A comparability study of 5 commercial KRAS tests

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

21 January 2018

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of interest in evidence-based evaluations of genetic tests

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO C

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Hurdles and complexities of codon 13 KRAS mutations

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.184

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/GIM.2012.184

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38083489&oldid=2201250134"